Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib study of BKM120 plus MEK162 in advanced solid tumors
NL-OMON43645Phase 1Active, not recruiting
- Sponsor
- Array BioPharma
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of buparlisib and binimetinib in Nonhematologic neoplasms, pancreatic cancer (PC), colorectal cancer (CRC) and 3 more, sponsored by Array BioPharma. Primary endpoint: Maximum tolerated dose and/or recommended phase 2 dose. Started Mar 2012; status: active, not recruiting.
02
Drugs
buparlisibbinimetinib
03
Conditions
Nonhematologic neoplasmspancreatic cancer (PC)colorectal cancer (CRC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON43645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43645.